Tags : P-III STYLE study

Celgene Reports Otezla (apremilast) Achieve 1EP in P-III STYLE Study

Shots: The P-III STYLE study involves assessing of Otezla 30mg bid vs PBO in moderate to severe plaque psoriasis patients in ratio (2:1) for 16 wks., evaluating its safety and efficacy P-III STYLE study results(N=300): improvement in 1EP of the ScPGA response (clear (0)/almost (1)/at least (2-point reduction)) @16wks.; met 2EP of whole body itch […]Read More